Black Diamond Therapeutics (BDTX) vs Corbus Pharmaceuticals (CRBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Black Diamond Therapeutics (BDTX) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 54.6% versus a loss of 60.7%. Over five years, BDTX leads with a -77.9% price change compared with -82.8% for CRBP. Black Diamond Therapeutics is the larger company by market cap ($103.7 million vs $101.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | CRBP |
|---|---|---|
| Share price | $1.81 | $5.27 |
| Market cap | $103.72M | $101.93M |
| 1-day change | -1.09% | -4.01% |
| YTD return | -25.51% | -35.26% |
| 1-year return | -54.64% | -60.73% |
| 5-year return | -77.87% | -82.78% |
| EPS (TTM) | $-0.75 | $-6.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $20.56 |
| 52-week low | $1.60 | $5.13 |
| Distance from 52-week high | -63.36% | -74.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +452.49% | +545.73% |
| Average volume | 624.32K | 756.54K |
| Shares outstanding | 57.30M | 19.34M |
| Employees | 21 | 36 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Healthcare · Biotechnology · 21 employees
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Healthcare · Biotechnology · 36 employees
BDTX vs CRBP FAQ
Which is bigger, Black Diamond Therapeutics or Corbus Pharmaceuticals?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $103.72M compared with $101.93M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, BDTX or CRBP?
BDTX returned -54.64% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Corbus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.